Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for Alzheimer’s agitation: GlobalData Read more
IA-2A positivity could help develop effective intervention strategies in type 1 diabetes progression: GlobalData Read more
DREAM-HF trial results highlight Mesoblast’s potential to differentiate in HF space: GlobalData Read more
